Literature DB >> 24112179

Interventions to improve chronic cyclosporine A nephrotoxicity through inhibiting renal cell apoptosis: a systematic review.

Zheng Xiao1, Cheng-wen Li, Juan Shan, Lei Luo, Li Feng, Jun Lu, Sheng-fu Li, Dan Long, You-ping Li.   

Abstract

OBJECTIVE: To reveal interventions for chronic cyclosporine A nephrotoxicity (CCN) and provide new targets for further studies, we analyzed all relevant studies about interventions in renal cell apoptosis. DATA SOURCES: We collected all relevant studies about interventions for cyclosporine A (CsA)-induced renal cell apoptosis in Medline (1966 to July 2010), Embase (1980 to July 2010) and ISI (1986 to July 2010), evaluated their quality, extracted data following PICOS principles and synthesized the data. STUDY SELECTION: We included all relevant studies about interventions in CsA-induced renal cell apoptosis no limitation of research design and language) and excluded the duplicated articles, meeting abstracts and reviews without specific data.
RESULTS: There were three kinds of intervention, include anti-oxidant (sulfated polysaccharides, tea polyphenols, apigenin, curcumin, spirulina, etc), biologics (recombinant human erythropoietin (rhEPO), a murine pan-specific transforming growth factor (TGF)-beta-neutralizing monoclonal antibody1D11, cartilage oligomeric matrix protein (COMP)-angiopoietin-1 and hepatocyte growth factor (HGF) gene), and other drugs (spironolactone, rosiglitazone, pirfenidone and colchicine). These interventions significantly improved the CCN, renal cell apoptosis and renal dysfunction through intervening in four apoptotic pathways in animals or protected renal cells from apoptosis induced by CsA and increased cell survival through respectively four pathways in vitro.
CONCLUSIONS: There are three group interventions for CCN. Especially anti-oxidant drugs can significantly improve CCN, renal cell apoptosis and renal dysfunction. Many drugs can improve CCN through intervening in Fas/Fas ligand or mitochondrial pathway with sufficient evidences. Angiotensin II, nitric oxide (NO) and endoplasmic reticulum (ER) pathways will be new targets for CCN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24112179

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  6 in total

1.  In vitro Anti-Tumor Effects of Statins on Head and Neck Squamous Cell Carcinoma: A Systematic Review.

Authors:  Ludmila Madeira Cardoso Pavan; Daniela Fortunato Rêgo; Silvia Taveira Elias; Graziela De Luca Canto; Eliete Neves Silva Guerra
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

2.  Management of Cyclosporine and Nifedipine-Induced Gingival Hyperplasia.

Authors:  Cüneyt Asim Aral; Erhan Dilber; Kübra Aral; Yagmur Sarica; Oya Nermin Sivrikoz
Journal:  J Clin Diagn Res       Date:  2015-12-01

3.  The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats.

Authors:  Sina Raeisi; Amir Ghorbanihaghjo; Hassan Argani; Siavoush Dastmalchi; Babollah Ghasemi; Teimour Ghazizadeh; Nadereh Rashtchizadeh; Mehran Mesgari Abbasi; Nasrin Bargahi; Mahboob Nemati; Ali Mota; Amir Mansour Vatankhah
Journal:  Bioimpacts       Date:  2016-08-25

4.  Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review.

Authors:  Daniela Fortunato Rêgo; Silvia Taveira Elias; AngéLica Amorim Amato; Graziela De Luca Canto; Eliete Neves Silva Guerra
Journal:  Oncol Lett       Date:  2016-12-20       Impact factor: 2.967

5.  Naringin attenuates renal interstitial fibrosis by regulating the TGF-β/Smad signaling pathway and inflammation.

Authors:  Ruichen Wang; Gaolei Wu; Tiantian Dai; Yitian Lang; Zhongchao Chi; Shilei Yang; Deshi Dong
Journal:  Exp Ther Med       Date:  2020-11-23       Impact factor: 2.447

6.  Early Diagnosis of Kidney Damage Associated with Tobacco Use: Preventive Application.

Authors:  Javier Tascón; Marta Prieto; Alfredo G Casanova; Francisco J Sanz; Miguel A Hernández Mezquita; Miguel Barrueco Ferrero; Manuel A Gomez-Marcos; Luis Garcia-Ortiz; Laura Vicente-Vicente; Ana I Morales
Journal:  J Pers Med       Date:  2022-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.